Immunocore Holdings (IMCR) Profit After Tax (2021 - 2026)

Immunocore Holdings (IMCR) has reported Profit After Tax for 6 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax rose 127.72% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.0 million (down 74.82% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
• Profit After Tax improved to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
• Over the last five years, Profit After Tax for IMCR reached as high as $13.0 million in Q1 2026 and fell as low as -$30.1 million in Q4 2025.
• A 5-year average of -$11.6 million and a median of -$15.5 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax slumped 291.35% — and 2024, when it jumped 185.32%.
• Year by year, Profit After Tax stood at -$29.6 million in 2022, then soared by 35.78% to -$19.0 million in 2023, then slipped by 25.22% to -$23.8 million in 2024, then dropped by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $13.0 million, -$30.1 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.